Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Active vitamin D and acute respiratory infections in dialysis patients.

Tsujimoto Y, Tahara H, Shoji T, Emoto M, Koyama H, Ishimura E, Tabata T, Nishizawa Y, Inaba M.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1361-7. doi: 10.2215/CJN.08871010. Epub 2011 May 26.

2.

Association between vitamin D receptor activator and the risk of infection-related hospitalizations among incident hemodialysis patients: a nested case-control study.

Normand I, Elftouh N, Laurin LP, Ouimet D, Harrak H, Lafrance JP.

Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):261-7. doi: 10.1002/pds.3576. Epub 2014 Jan 27.

PMID:
24470433
3.

Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study.

Messa P, Cozzolino M, Brancaccio D, Cannella G, Malberti F, Costanzo AM, di Luzio Paparatti U, Festa V, Gualberti G, Mazzaferro S; FARO Study Group..

BMC Nephrol. 2015 Feb 6;16:11. doi: 10.1186/s12882-015-0006-8.

4.

Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients.

Ogawa T, Kyono A, Sato M, Sugimoto H, Otsuka K, Nitta K.

Clin Exp Nephrol. 2012 Oct;16(5):779-85. doi: 10.1007/s10157-012-0626-2. Epub 2012 Mar 29.

PMID:
22457088
5.

Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease.

Sueta S, Morozumi K, Takeda A, Horike K, Otsuka Y, Shinjo H, Murata M, Kato Y, Goto K, Inaguma D; Aichi cohort study of prognosis in patients newly initiated into dialysis (AICOPP) study group..

Clin Exp Nephrol. 2015 Jun;19(3):371-8. doi: 10.1007/s10157-014-0994-x. Epub 2014 Jun 11.

PMID:
24916005
6.

Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin d.

Rudnicki M, Kerschbaum J, Hausdorfer J, Mayer G, König P.

Perit Dial Int. 2010 Sep-Oct;30(5):541-8. doi: 10.3747/pdi.2009.00108. Epub 2010 Mar 12.

PMID:
20228174
7.

Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.

Shinaberger CS, Kopple JD, Kovesdy CP, McAllister CJ, van Wyck D, Greenland S, Kalantar-Zadeh K.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1769-76. doi: 10.2215/CJN.01760408. Epub 2008 Aug 13.

8.

Adherence to treatment and hospitalization risk in hemodialysis patients.

Vaiciuniene R, Kuzminskis V, Ziginskiene E, Skarupskiene I, Bumblyte IA.

J Nephrol. 2012 Sep-Oct;25(5):672-8. doi: 10.5301/jn.5000038.

PMID:
21983989
9.

Family income and survival in Brazilian Peritoneal Dialysis Multicenter Study Patients (BRAZPD): time to revisit a myth?

de Andrade Bastos K, Qureshi AR, Lopes AA, Fernandes N, Barbosa LM, Pecoits-Filho R, Divino-Filho JC; Brazilian Peritoneal Dialysis Multicenter Study (BRAZPD) Group..

Clin J Am Soc Nephrol. 2011 Jul;6(7):1676-83. doi: 10.2215/CJN.09041010. Epub 2011 Jun 23.

10.

Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?

Lomonte C, Vernaglione L, Chimienti D, Bruno A, Cocola S, Teutonico A, Cazzato F, Basile C.

Clin J Am Soc Nephrol. 2008 May;3(3):794-9. doi: 10.2215/CJN.04150907. Epub 2008 Mar 5.

11.

Predialysis Vitamin D Receptor Activator Treatment and Cardiovascular Events after Dialysis Initiation: A Multicenter Observational Study.

Inaguma D, Tanaka A, Shinjo H, Kato A, Murata M; Aichi cohort study of prognosis in patients newly initiated into dialysis (AICOPP) group..

Nephron. 2016;133(1):35-43. doi: 10.1159/000445507. Epub 2016 Apr 8.

PMID:
27054694
12.

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A.

Clin J Am Soc Nephrol. 2010 May;5(5):905-11. doi: 10.2215/CJN.06510909. Epub 2010 Mar 4.

13.

Dietary intake and supplement use of vitamins C and E and upper respiratory tract infection.

Fondell E, Bälter O, Rothman KJ, Bälter K.

J Am Coll Nutr. 2011 Aug;30(4):248-58.

PMID:
21917705
14.

Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis.

St Peter WL, Li S, Liu J, Gilbertson DT, Arneson TJ, Collins AJ.

Pharmacotherapy. 2009 Feb;29(2):154-64. doi: 10.1592/phco.29.2.154.

PMID:
19170585
15.

Vitamins are associated with survival in patients with end-stage renal disease: a 4-year prospective study.

Domröse U, Heinz J, Westphal S, Luley C, Neumann KH, Dierkes J.

Clin Nephrol. 2007 Apr;67(4):221-9.

PMID:
17474558
16.

Dialysis modality and outcomes in kidney transplant recipients.

Molnar MZ, Mehrotra R, Duong U, Bunnapradist S, Lukowsky LR, Krishnan M, Kovesdy CP, Kalantar-Zadeh K.

Clin J Am Soc Nephrol. 2012 Feb;7(2):332-41. doi: 10.2215/CJN.07110711. Epub 2011 Dec 8.

17.

Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.

Brancaccio D, Cozzolino M, Cannella G, Messa P, Bonomini M, Cancarini G, Caruso MR, Cascone C, Costanzo AM, di Luzio Paparatti U, Mazzaferro S; FARO Study Group..

Blood Purif. 2011;32(2):124-32. doi: 10.1159/000325454. Epub 2011 May 28.

PMID:
21625082
18.

Thrombolysis for lower extremity bypass graft occlusion.

Koraen L, Kuoppala M, Acosta S, Wahlgren CM.

J Vasc Surg. 2011 Nov;54(5):1339-44. doi: 10.1016/j.jvs.2011.05.008. Epub 2011 Jul 1.

20.

Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients.

Rogacev KS, Pinsdorf T, Weingärtner O, Gerhart MK, Welzel E, van Bentum K, Popp J, Menzner A, Fliser D, Lütjohann D, Heine GH.

Clin J Am Soc Nephrol. 2012 Jun;7(6):943-8. doi: 10.2215/CJN.05170511. Epub 2012 Mar 29.

Supplemental Content

Support Center